Spruce Biosciences (SPRB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SPRB Spruce Biosciences

Watchlist

0.491
+0.001+0.20%

Close Nov 21 16:00 ET

0.480
-0.012-2.34%

Post 16:09 ET

20.28MMarket Cap-516P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics
Yahoo FinanceNov 21 04:06 ET
Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?
TipRanksNov 13 01:01 ET
Spruce Biosciences | 10-Q: Q3 2024 Earnings Report
SECNov 12 11:47 ET · Announcements
RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)
TipRanksNov 12 06:38 ET · Ratings
Spruce Biosciences Reports Q3 EPS (21c), Consensus (24c)
TipRanksNov 11 08:11 ET
Express News | Spruce Biosciences: Cash, Cash Equivalents Expected to Allow Co to Fund Operating Plan Through 2025 End
ReutersNov 11 08:02 ET

Comments

73372627

Aug 10 13:31

$Zebra Technologies (ZBRA.US)$ and the true of the Spruce analysis

I will never undestend why this company is not investigated for manipulating the market on theirs own interest.
Let's go see why such investigation is neccessary and I hope Zebra will complain.
Spruce it is an Short-selling company which allways made negative reports or analysis in order to influence the market for theyr's own profit. Parallel with Short-selling they are also in real estate managment in New York where they loose b...

Jaguar8

Jun 4 06:13

NEWS

$Spruce Biosciences (SPRB.US)$
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...